Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib
- Author(s)
- Bhullar, HK; Bhabha, F; McCormack, C; Prince, HM;
- Details
- Publication Year 2025-02,Volume 66,Issue #1,Page 32-35
- Journal Title
- Australasian Journal of Dermatology
- Publication Type
- Case report
- Abstract
- Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
- Keywords
- Humans; Female; Aged; *Pyrazines/therapeutic use; *Benzamides/therapeutic use; Remission Induction; Carbamates/therapeutic use; Waldenstrom Macroglobulinemia/drug therapy; Protein Kinase Inhibitors/therapeutic use; Sneddon Wilkinson disease; acalabrutinib; monoclonal gammopathy of undetermined significance; subcorneal pustular dermatoses
- Department(s)
- Surgical Oncology; Haematology
- Publisher's Version
- https://doi.org/10.1111/ajd.14386
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-10 02:43:10
Last Modified: 2025-03-14 07:08:01